Is today’s pharmaceutical commercial model going extinct?

Is today’s pharmaceutical commercial model going extinct?

Novel cell and gene therapy options are significantly improving treatment outcomes, and in some cases providing cures via one-time treatment to rare diseases previously considered untreatable. While these one-time therapies, particularly when curative, have the potential to be beneficial to patients with serious life-threatening diseases, a number of characteristics differentiate them from conventional chronic therapies:

  • One-time therapies typically treat an existing prevalent pool of patients at launch.
  • One-time therapies typically have treatment regimens of significantly shorter duration relative to chronic therapies.
  • The available patient population diminishes, sometimes rapidly, over the course of the curative therapy lifecycle as the pre-launch patient prevalent pool is depleted.

In this paper, we aim to present 7 disruptions and some mitigation strategies related to
one-time therapies. For the full piece, click the link below.

Download PDF